GlassScriptPhysician profile
Timothy Andrassy
NPI 1396444154
$4,407.32
in general payments reported to CMS, 2019-2025
18 companies · $1,801 in 2025
The $1,801 reported for 2025 was more than what 91% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,092 · 2024: $1,515 · 2025: $1,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,308 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,308.32 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $779.85 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $563.27 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $557.08 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $520.77 | 2023-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $306.33 | 2023-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $284.17 | 2024-2025 | Fanapt, Hetlioz |
| Lundbeck LLC | $248.72 | 2023-2025 | Rexulti |
| Livanova USA, INC. | $198.84 | 2024-2025 | Vns Therapy Symmetry Model 8103 Generator |
| Alkermes, INC. | $194.87 | 2023-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $177.74 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $148.00 | 2023-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $92.74 | 2023-2025 | Caplyta |
| Idorsia Pharmaceuticals US INC | $90.38 | 2023 | Quviviq |
| Corium, LLC | $81.77 | 2023-2025 | Azstarys |
| Almatica Pharma LLC | $73.48 | 2023-2024 | Loreev Xr |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $48.89 | 2025 | Cobenfy |
| Tempus Ai, INC | $27.18 | 2024 | |
| Neos Therapeutics, LP | $13.24 | 2024 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Andrassy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.